Esketamine, the (S) enantiomer of racemic ketamine, is FDA-approved for adults with TRD and adults with MDD with suicidal thoughts or actions in combination with an oral antidepressant.

Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in treatment-resistant depression, a study found.

Across the seven trials, esketamine was associated with a significant reduction in PPD at 1 week after delivery at a risk ratio vs placebo of 0.459 (P < .05).

Esketamine-treated women had lower EPDS scores on day 7 and day 42 (median difference, -3). Individuals receiving esketamine also had reduced HDRS scores 42 days after delivery (mean difference, -4).

Spravato, a nasal spray esketamine, was found to work better than Seroquel for treatment-resistant depression, a study in the New England Journal of Medicine finds.

Credit: pxhere.com Esketamine plus SNRI cohort showed better survival probability than esketamine pls SSRI group. Credit: JAMA Psychiatry (2025). DOI: 10.1001/jamapsychiatry.2025.0200 ...

For the key secondary endpoint of the trial, esketamine monotherapy was significantly better than placebo by day 2, about 24 hours after the first dose. This was marked by a 3.8-point and 3.4 ...

Esketamine nasal spray, administered in combination with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin–norepinephrine reuptake inhibitor (SNRI), is the only treatment ...

Spravato (esketamine) is a prescription nasal spray that treats depression in adults. Learn about dosage, side effects, and more.

Compared with saline, administration of low-dose esketamine significantly reduced the composite outcome of desaturation and hypotension (8.2% vs. 21%; risk difference = –12.8 percentage points ...

Spravato, a nasal spray esketamine, was found to work better than Seroquel for treatment-resistant depression, a study in the New England Journal of Medicine finds.

Meeting Coverage > Psych Congress Esketamine Also Effective Without Adjunctive Antidepressant — Trial data may expand use, with "opportunity to truly individualize treatment" by Kristen Monaco ...